| Listen Aphasia Pilot Study (NCT07732140) | Dana-Farber Cancer Institute | 2027-01-01 |
| Breast and Cervical Cancer Stigma in Rwanda (NCT07663006) | Dana-Farber Cancer Institute | 2026-11-01 |
| Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy (NCT07548476) | Dana-Farber Cancer Institute | 2026-10-02 |
| Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes (NCT07729150) | Dana-Farber Cancer Institute | 2026-10-01 |
| Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda (NCT07562399) | Dana-Farber Cancer Institute | 2026-09-20 |
| Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention (NCT07519200) | Dana-Farber Cancer Institute | 2026-09-18 |
| Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer (NCT07499999) | Dana-Farber Cancer Institute | 2026-09-09 |
| SMARCA4/2 Inhibitor for POU2F3-Positive SCLC (NCT07551635) | Dana-Farber Cancer Institute | 2026-09-04 |
| Neurocognitive Assessment CNSL and LGG (NCT07710131) | Dana-Farber Cancer Institute | 2026-09-01 |
| Development and Testing of Nutritional Algorithms (NACHO) (NCT05825469) | Dana-Farber Cancer Institute | 2026-09-01 |
| RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer (NCT07735624) | Dana-Farber Cancer Institute | 2026-09-01 |
| my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults (NCT07516353) | Dana-Farber Cancer Institute | 2026-08-20 |
| Supporting Health Including Endocrine Treatment for Long Duration (NCT07482384) | Dana-Farber Cancer Institute | 2026-08-04 |
| Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing (NCT06117709) | Dana-Farber Cancer Institute | 2026-08-01 |
| BRIDGE-SIC Efficacy Trial (NCT07735442) | Dana-Farber Cancer Institute | 2026-07-31 |
| Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) (NCT07513324) | Dana-Farber Cancer Institute | 2026-07-01 |
| The DISCOVER Study (NCT07390643) | Dana-Farber Cancer Institute | 2026-07-01 |
| Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma (NCT07601100) | Dana-Farber Cancer Institute | 2026-06-26 |
| ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs (NCT07232043) | Dana-Farber Cancer Institute | 2026-06-01 |
| PH 2 Pemigatinib in SDH-deficient GIST (NCT07434843) | Dana-Farber Cancer Institute | 2026-05-19 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy (NCT07426484) | Dana-Farber Cancer Institute | 2026-04-23 |
| ALL Backbone in AYAs (NCT07227584) | Dana-Farber Cancer Institute | 2026-04-03 |
| Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC (NCT07465276) | Dana-Farber Cancer Institute | 2026-03-26 |
| Ph 2 Elacestrant in ER Positive Uterine Sarcomas (NCT07467772) | Dana-Farber Cancer Institute | 2026-03-25 |
| On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety (NCT07305740) | Dana-Farber Cancer Institute | 2026-03-11 |
| Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC (NCT07397611) | Dana-Farber Cancer Institute | 2026-03-09 |
| Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial (NCT07442578) | Dana-Farber Cancer Institute | 2026-03-04 |
| Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study (NCT07412041) | Dana-Farber Cancer Institute | 2026-01-22 |
| Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT) (NCT06807294) | Dana-Farber Cancer Institute | 2026-01-16 |
| Cryocompression for CIPN (NCT07064798) | Dana-Farber Cancer Institute | 2025-10-22 |
| Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication (NCT07147023) | Dana-Farber Cancer Institute | 2025-09-15 |
| Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study (NCT07123649) | Dana-Farber Cancer Institute | 2025-09-11 |
| HEME Home Transfusion Program (NCT06487247) | Dana-Farber Cancer Institute | 2025-09-10 |
| 177LuPSMA in Renal Cell Carcinoma (NCT06964958) | Dana-Farber Cancer Institute | 2025-07-31 |
| Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study (NCT06623097) | Dana-Farber Cancer Institute | 2025-07-23 |
| Sleep Treatment Education Program for Cancer Survivors: STEP-Together (NCT06736548) | Dana-Farber Cancer Institute | 2025-06-25 |
| Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial (NCT06923397) | Dana-Farber Cancer Institute | 2025-06-05 |
| BOLSTER: Learning New Skills to Thrive (NCT06936878) | Dana-Farber Cancer Institute | 2025-05-12 |
| Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma (NCT06831552) | Dana-Farber Cancer Institute | 2025-04-30 |
| Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors (NCT06609473) | Dana-Farber Cancer Institute | 2025-04-07 |
| Clonal Hematopoiesis Chemotherapy and Radiation Effects Study (NCT07675967) | Dana-Farber Cancer Institute | 2025-04-04 |
| EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations (NCT06716580) | Dana-Farber Cancer Institute | 2025-04-01 |
| Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing (NCT06907797) | Dana-Farber Cancer Institute | 2025-04-01 |
| Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study (NCT06523868) | Dana-Farber Cancer Institute | 2025-03-31 |
| Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers (NCT06722014) | Dana-Farber Cancer Institute | 2025-03-27 |
| REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors (NCT06710548) | Dana-Farber Cancer Institute | 2025-03-17 |
| Pilot of a Trial Enrollment Diversity Dashboard (NCT06795139) | Dana-Farber Cancer Institute | 2025-03-01 |
| Sexual Health and Rehabilitation Online (SHAREonline) (NCT06458049) | Dana-Farber Cancer Institute | 2025-02-19 |
| UNTIRE: Cancer-related Fatigue With Digital Treatment (NCT05584540) | Dana-Farber Cancer Institute | 2025-01-30 |
| Dance Study for Post-surgical Pain in Breast Cancer Survivors (NCT06758102) | Dana-Farber Cancer Institute | 2025-01-22 |
| Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer (NCT06543537) | Dana-Farber Cancer Institute | 2025-01-17 |
| Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin (NCT06677190) | Dana-Farber Cancer Institute | 2024-12-20 |
| The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial (NCT06565052) | Dana-Farber Cancer Institute | 2024-12-15 |
| Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE) (NCT06469307) | Dana-Farber Cancer Institute | 2024-12-09 |
| Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL (NCT06475235) | Dana-Farber Cancer Institute | 2024-10-18 |
| Home Transfusion for HEME (NCT05509439) | Dana-Farber Cancer Institute | 2024-10-18 |
| Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer (NCT06321484) | Dana-Farber Cancer Institute | 2024-10-09 |
| Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study (NCT06450171) | Dana-Farber Cancer Institute | 2024-09-27 |
| ALPINE: Maintenance Letrozole/Abemaciclib (NCT06366347) | Dana-Farber Cancer Institute | 2024-09-25 |
| PRISM for Depression and Anxiety in Young Adults With Cancer (NCT06502483) | Dana-Farber Cancer Institute | 2024-09-06 |
| The COMPASSION Study (NCT06507930) | Dana-Farber Cancer Institute | 2024-09-01 |
| PediCARE Health Equity Intervention in High-Risk Neuroblastoma (NCT06335745) | Dana-Farber Cancer Institute | 2024-09-01 |
| Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (NCT06318871) | Dana-Farber Cancer Institute | 2024-08-28 |
| Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer (NCT06488378) | Dana-Farber Cancer Institute | 2024-08-13 |
| The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer (NCT06439693) | Dana-Farber Cancer Institute | 2024-08-08 |
| Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients (NCT06468618) | Dana-Farber Cancer Institute | 2024-08-06 |
| MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies (NCT06543511) | Dana-Farber Cancer Institute | 2024-07-29 |
| Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial (NCT06202183) | Dana-Farber Cancer Institute | 2024-07-22 |
| BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) (NCT05922761) | Dana-Farber Cancer Institute | 2024-05-31 |
| LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer (NCT06303713) | Dana-Farber Cancer Institute | 2024-05-22 |
| PediRISE Feasibility (NCT06283251) | Dana-Farber Cancer Institute | 2024-05-15 |
| Cardiotoxicities in Patients Receiving BTKi (NCT05521178) | Dana-Farber Cancer Institute | 2024-05-01 |
| Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D) (NCT06322888) | Dana-Farber Cancer Institute | 2024-03-28 |
| Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments (NCT06138561) | Dana-Farber Cancer Institute | 2024-03-05 |
| Marizomib Central Nervous System (CNS) (NCT05050305) | Dana-Farber Cancer Institute | 2024-03-01 |
| CIML NK Cells With Venetoclax for AML (NCT06152809) | Dana-Farber Cancer Institute | 2024-02-20 |
| PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC (NCT06239220) | Dana-Farber Cancer Institute | 2024-02-16 |
| INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy (NCT06246084) | Dana-Farber Cancer Institute | 2024-02-15 |
| RecoverPC: Relugolix vs GnRH Agonist in Quality of Life (NCT05765500) | Dana-Farber Cancer Institute | 2024-02-12 |
| Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial (NCT06026111) | Dana-Farber Cancer Institute | 2024-02-01 |
| Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation (NCT06138587) | Dana-Farber Cancer Institute | 2024-01-24 |
| CV CARE: CardioVascular Care in PC Patients (NCT06202820) | Dana-Farber Cancer Institute | 2024-01-18 |
| Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial (NCT06040125) | Dana-Farber Cancer Institute | 2024-01-01 |
| High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study (NCT05740839) | Dana-Farber Cancer Institute | 2023-12-04 |
| Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals (NCT06122896) | Dana-Farber Cancer Institute | 2023-11-21 |
| Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer (NCT06038318) | Dana-Farber Cancer Institute | 2023-10-16 |
| TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (NCT06001762) | Dana-Farber Cancer Institute | 2023-10-05 |
| Insomnia Prevention in Children With Acute Lymphoblastic Leukemia (NCT05866887) | Dana-Farber Cancer Institute | 2023-09-26 |
| A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest (NCT05899361) | Dana-Farber Cancer Institute | 2023-08-30 |
| Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC (NCT05726370) | Dana-Farber Cancer Institute | 2023-05-20 |
| Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia (NCT05734495) | Dana-Farber Cancer Institute | 2023-05-02 |
| Implantable Microdevice for TNBC - Pilot Study (NCT05774886) | Dana-Farber Cancer Institute | 2023-05-01 |
| Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing (NCT05759143) | Dana-Farber Cancer Institute | 2023-05-01 |
| InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer (NCT05463796) | Dana-Farber Cancer Institute | 2023-04-25 |
| STOP-HER2: Stopping Trastuzumab in HER2+ MBC (NCT05721248) | Dana-Farber Cancer Institute | 2023-04-19 |
| CAR- PRISM (PRecision Intervention Smoldering Myeloma) (NCT05767359) | Dana-Farber Cancer Institute | 2023-04-19 |
| TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (NCT05535192) | Dana-Farber Cancer Institute | 2023-03-20 |
| Sleep Treatment Education Program-1 (STEP-1) (NCT05519982) | Dana-Farber Cancer Institute | 2023-03-10 |
| PROFAST Intervention in Precursor Multiple Myeloma (NCT05565638) | Dana-Farber Cancer Institute | 2023-03-06 |
| Patient-Centered Surgical Prehabilitation (NCT05715684) | Dana-Farber Cancer Institute | 2023-03-01 |